Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial

What Was Tested

The paper reports a study of Insulin Lispro, published as a randomized controlled trial.

Insulin initiation in patients with type 2 diabetes is often delayed because of concerns about injections.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This was planned as a 24-month, open-label, randomized study in adults with diabetes inadequately controlled by one or more oral antihyperglycemic medications (OAMs).

Following a 2-week baseline period, patients continued OAMs and were randomized to AIR insulin (n = 208) or insulin lispro (n = 203) before meals.

How the Study Was Run

The design is described as randomized and open-label.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Insulin Lispro was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The primary end point was hemoglobin A1C (A1C) change from baseline to 6 months.

What Was Measured

PubMed files the paper under topics including Administration, Inhalation, Body Mass Index, Diabetes Mellitus, Type 2, Forced Expiratory Volume, Glycated Hemoglobin, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Lispro.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Lispro compound page, all human trials.